February 2026 - Page 5 of 6

Paramount sweetens hostile bid to stop Netflix-Warner Bros. deal

07

Feb

Paramount Raises Bid to Block Netflix-Warner Bros. Alliance

A high-stakes battle is unfolding in the global media industry, with Paramount escalating its efforts to disrupt Warner Bros. Discovery’s planned sale to Netflix. New financial incentives and strategic guarantees underscore how fiercely contested the future of one of Hollywood’s most influential content libraries has become.Paramount has once again intensified its pressure in its hostile chase of Warner Bros. Discovery, rolling out new financial commitments aimed at winning over shareholders as time runs down on a potential landmark deal with Netflix. This latest step highlights both the scale of Paramount’s ambitions and the increasingly forceful tactics driving consolidation across the…

How do investors compare value, growth, and quality styles over a full cycle?

05

Feb

By Jean Thompson

Investments and Business

The Full Cycle View: Value, Growth, and Quality Investment Styles

Investors often categorize equities into value, growth, and quality styles to structure portfolios and expectations. Comparing these styles over a full market cycle—from expansion to peak, contraction, and recovery—helps investors understand why leadership rotates and how diversification can improve outcomes. A full cycle typically spans several years and includes changing economic growth, inflation, interest rates, and risk appetite.Defining the Three StylesValue: Stocks trading at relatively low prices compared with fundamentals such as earnings, book value, or cash flow. Common metrics include price-to-earnings and price-to-book ratios.Growth: Companies expected to grow revenues and earnings faster than the market average, often reinvesting profits…

Therapeutic vaccines: the concept gaining ground in oncology

05

Feb

By Jean Thompson

Science and Technology

The Evolving Role of Therapeutic Vaccines in Cancer

Therapeutic cancer vaccines represent a shift from prevention to active treatment: instead of preventing infection or disease onset, they aim to train the patient’s immune system to recognize and destroy existing tumor cells. Over the past decade, advances in immunology, genomic sequencing, and delivery technologies have moved therapeutic vaccines from concept and small trials toward real-world approvals and large randomized studies. This article explains the core concepts, describes leading modalities and examples, examines clinical data and challenges, and highlights where the field is likely to go next.What defines a therapeutic cancer vaccine?A therapeutic cancer vaccine stimulates the immune system to…

Denmark: CSR cases leading circular economy and sustainable design

05

Feb

By Jean Thompson

Social Responsibility

Denmark’s Approach: CSR-Led Circular Economy & Sustainable Design

Denmark has evolved into a global testbed where corporate social responsibility is transformed into commercially scalable circular‑economy strategies and sustainable design solutions, driven by public ambition, informed consumers, collaborative institutions, and inventive companies and startups that generate widely referenced and frequently emulated examples, while the Danish method weaves together product reengineering, fresh business models, infrastructure investments, and supportive policy frameworks to cut waste, extend material lifecycles, and reduce carbon emissions without sacrificing competitiveness.Corporate leaders translating CSR into circular business modelsLEGO — The LEGO Group has tied CSR to product innovation and supply-chain change. Its public target to transition core products…

Why are secondaries becoming a mainstream private market strategy?

05

Feb

By Jean Thompson

Investments and Business

Secondaries as a Mainstream Private Market Strategy: An Analysis

Secondaries refer to transactions in which investors buy and sell existing interests in private market funds or assets, rather than committing capital to new, primary investments. Historically, these transactions were niche, often driven by distressed sellers seeking liquidity. Today, secondaries have evolved into a core private market strategy, spanning private equity, private credit, real assets, and venture capital.The rise of secondaries signals broader shifts in the functioning of private markets, in the way investors oversee their portfolios, and in how capital pursues efficiency amid an unpredictable macroeconomic environment.The Underlying Dynamics Propelling Widespread AdoptionSeveral long-term forces explain why secondaries have moved…

France: How companies finance innovation while managing labor and compliance obligations

05

Feb

By Jean Thompson

Investments and Business

France: Corporate Innovation, Labor, Compliance

France blends an extensive public safety net and fairly protective labor regulations with a robust landscape of public incentives, bank lending, venture capital, and corporate R&D. This combination offers both advantages and limitations: firms can tap into diverse funding avenues to support innovation, yet they must also navigate substantial labor‑related expenses and compliance duties that shape the cost structure and scheduling of innovation initiatives.Scale and contextR&D intensity: France’s overall spending on research and development typically sits a bit above 2 percent of GDP, falling short of the 3 percent benchmark pursued by certain European Union members. As a result, public…